Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The CRL did not identify any outstanding scientific issues with the product.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Subscribe To Our Newsletter & Stay Updated